Patents by Inventor Zhiguo Bian
Zhiguo Bian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11986907Abstract: In the automatic welding method and device for prestressed tubular piles provided in the present application, which is applied in welding equipment, a detection is conducted around a connection position between prestressed tubular piles and a position of a target welding seam is obtained. Then the target welding seam is welded around the prestressed tubular piles according to the position of the target welding seam.Type: GrantFiled: February 14, 2023Date of Patent: May 21, 2024Assignee: Guangzhou Municipal Engineering Testing Co., Ltd.Inventors: Xiaoli Sun, Zhiguo Zhou, Jun Yang, Liangjun Hu, Jixi Shao, Decun Bian, Yuzhu Zhang, Hao Li, Lu Liu, Yongxiao Du, Xiaohua Yuan
-
Publication number: 20240109877Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4A, R4b, and R5, are as defined herein, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of CLL.Type: ApplicationFiled: March 21, 2023Publication date: April 4, 2024Inventors: Zhiguo Bian, Jason P. Burke, Zhaozhong J. Jia, Xingyu Jiang, Matthew H. Katcher, Venkat Reddy Mali, Violeta L. Marin, Elizabeth L. Noey, Akinori Okano, Alexey A. Rivkin, Spencer O. Scholz, Kevin R. Woller, Xianrui Zhao, Ashley M. Adams, Berenger Biannic, Shahab Mortezaei, Joshua N. Payette, Jeffery A. Zablocki
-
Publication number: 20230330099Abstract: The present disclosure provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present disclosure also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.Type: ApplicationFiled: December 9, 2022Publication date: October 19, 2023Inventors: Taekyu Lee, James C. Tarr, KyuOk Jeon, James M. Salovich, Subrata Shaw, Nagarathanam Veerasamy, Kwangho Kim, Plamen P. Christov, Edward T. Olejniczak, Bin Zhao, Stephen W. Fesik, Zhiguo Bian
-
Patent number: 11596639Abstract: The present disclosure provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present disclosure also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.Type: GrantFiled: March 3, 2017Date of Patent: March 7, 2023Assignee: Vanderbilt UniversityInventors: Taekyu Lee, James C. Tarr, KyuOk Jeon, James M. Salovich, Subrata Shaw, Nagarathanam Veerasamy, Kwangho Kim, Plamen P. Christov, Edward T. Olejniczak, Bin Zhao, Stephen W. Fesik, Zhiguo Bian
-
Publication number: 20230039309Abstract: The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.Type: ApplicationFiled: November 4, 2021Publication date: February 9, 2023Inventors: Taekyu Lee, Zhiguo Bian, Johannes Belmar, Plamen P. Christov, Nicholas F. Pelz, Subrata Shaw, Kwangho Kim, James C. Tarr, Edward T. Olejniczak, Bin Zhao, Stephen W. Fesik
-
Patent number: 11208415Abstract: The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.Type: GrantFiled: November 19, 2019Date of Patent: December 28, 2021Assignee: Vanderbilt UniversityInventors: Taekyu Lee, Zhiguo Bian, Johannes Belmar, Plamen P. Christov, Nicholas F. Pelz, Subrata Shaw, Kwangho Kim, James C. Tarr, Edward T. Olejniczak, Bin Zhao, Stephen W. Fesik
-
Publication number: 20210283138Abstract: The present disclosure provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present disclosure also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.Type: ApplicationFiled: March 3, 2017Publication date: September 16, 2021Inventors: Taekyu Lee, James C. Tarr, KyuOk Jeon, James M. Salovich, Subrata Shaw, Nagarathanam Veerasamy, Kwangho Kim, Plamen P. Christov, Edward T. Olejniczak, Bin Zhao, Stephen W. Fesik, Zhiguo Bian
-
Patent number: 10844032Abstract: The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.Type: GrantFiled: July 2, 2018Date of Patent: November 24, 2020Assignee: Vanderbilt UniversityInventors: Taekyu Lee, Nicholas F. Pelz, Johannes Belmar, Zhiguo Bian, Edward T. Olejniczak, Stephen W. Fesik, Brian A. Chauder
-
Publication number: 20200140447Abstract: The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.Type: ApplicationFiled: November 19, 2019Publication date: May 7, 2020Inventors: Taekyu Lee, Zhiguo Bian, Johannes Belmar, Plamen P. Christov, Nicholas F. Pelz, Subrata Shaw, Kwangho Kim, James C. Tarr, Edward T. Olejniczak, Bin Zhao, Stephen W. Fesik
-
Patent number: 10533010Abstract: The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.Type: GrantFiled: March 26, 2015Date of Patent: January 14, 2020Assignee: Vanderbilt UniversityInventors: Taekyu Lee, Zhiguo Bian, Johannes Belmar, Plamen P. Christov, Nicholas F. Pelz, Subrata Shaw, Kwangho Kim, James C. Tarr, Edward T. Olejniczak, Bin Zhao, Stephen W. Fesik
-
Publication number: 20180312485Abstract: The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.Type: ApplicationFiled: July 2, 2018Publication date: November 1, 2018Inventors: Taekyu Lee, Nicholas F. Pelz, Johannes Belmar, Zhiguo Bian, Edward T. Olejniczak, Stephen W. Fesik, Brian A. Chauder
-
Patent number: 10093640Abstract: The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.Type: GrantFiled: September 20, 2013Date of Patent: October 9, 2018Assignee: Vanderbilt UniversityInventors: Taekyu Lee, Nicholas F. Pelz, Johannes Belmar, Zhiguo Bian, Edward T. Olejniczak, Stephen W. Fesik, Brian A. Chauder
-
Patent number: 9949965Abstract: The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.Type: GrantFiled: October 16, 2015Date of Patent: April 24, 2018Assignee: Vanderbilt UniversityInventors: Taekyu Lee, Jason P. Burke, Edward T. Olejniczak, Johannes Belmar, Zhiguo Bian, Stephen W. Fesik
-
Publication number: 20170174689Abstract: The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.Type: ApplicationFiled: March 26, 2015Publication date: June 22, 2017Inventors: Taekyu Lee, Zhiguo Bian, Johannes Belmar, Plamen P. Christov, Nicholas F. Pelz, Subrata Shaw, Kwangho Kim, James C. Tarr, Edward T. Olejniczak, Bin Zhao, Stephen W. Fesik
-
Publication number: 20160106731Abstract: The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.Type: ApplicationFiled: October 16, 2015Publication date: April 21, 2016Inventors: Taekyu Lee, Jason P. Burke, Edward T. Olejniczak, Johannes Belmar, Zhiguo Bian, Stephen W. Fesik
-
Publication number: 20150336925Abstract: The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.Type: ApplicationFiled: September 20, 2013Publication date: November 26, 2015Applicant: VANDERBILT UNIVERSITYInventors: Taekyu Lee, Nicholas F. Pelz, Johannes Belmar, Zhiguo Bian, Edward T. Olejniczak, Stephen W. Fesik, Brian A. Chauder